Physician profile
Mary E Hardy
NPI 1417363698
$2,410.19
in general payments reported to CMS, 2019-2025
13 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $1,300 · 2021: $154 · 2022: $64.79 · 2023: $35.59 · 2024: $172 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340 · Entertainment: $44.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.67 |
| Entertainment | $44.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,392.31 | 2019-2025 | Precision 1, Precision7 |
| Visioneering Technologies, INC. | $283.34 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $214.66 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $124.00 | 2021-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $71.49 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $69.54 | 2024-2025 | Infuse |
| Optos, INC. | $58.59 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $54.95 | 2019-2020 | |
| Synergeyes, INC. | $49.30 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Kala Pharmaceuticals, INC. | $21.83 | 2021 | |
| Shire North American Group INC | $21.13 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $10.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.